We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

53 hedge funds and large institutions have $52.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

26% more funds holding

Funds holding: 42 → 53 (+11)

10% less capital invested

Capital invested by funds: $58.4M → $52.7M (-$5.69M)

Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
14
Reduced
9
Closed
4
Calls
$105K
Puts
–
Net Calls
+$105K
Net Calls Change
-$104K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$2.47M
2
KCM
Kennedy Capital Management
Missouri
+$722K
3
Renaissance Technologies
Renaissance Technologies
New York
+$582K
4
Jane Street
Jane Street
New York
+$516K
5
OAM
Oxford Asset Management
United Kingdom
+$387K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$660K
2
Deutsche Bank
Deutsche Bank
Germany
-$415K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$221K
4
Millennium Management
Millennium Management
New York
-$215K
5
VF
Virtu Financial
New York
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$58K +$30.6K +10,454 +95%
WT
27
Washington Trust
Rhode Island
$51K -$36.3K -12,400 -39%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$37K +$40.9K +13,940 New
GC
29
Guggenheim Capital
Illinois
$32K -$4.34K -1,480 -11%
Citadel Advisors
30
Citadel Advisors
Florida
$31K +$33.5K +11,418 New
SIM
31
Spark Investment Management
New York
$31K +$34.3K +11,700 New
UBS Group
32
UBS Group
Switzerland
$30K +$11.6K +3,973 +55%
PAM
33
Panagora Asset Management
Massachusetts
$12K +$13.2K +4,507 New
Manulife (Manufacturers Life Insurance)
34
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K +$6.88K +2,346 +787%
CLOS
35
Compagnie Lombard Odier SCmA
Switzerland
$4K +$2.35K +800 +100%
AG
36
Advisor Group
Arizona
$1K – – –
Barclays
37
Barclays
United Kingdom
$1K – – –
AC
38
Avestar Capital
New York
$1K +$1.76K +600 New
MPWT
39
MassMutual Private Wealth & Trust
Connecticut
$54 – – –
GEA
40
Glen Eagle Advisors
New Jersey
$27 – – –
Millennium Management
41
Millennium Management
New York
– -$215K -67,352 Closed
VF
42
Virtu Financial
New York
– -$54K -16,838 Closed
TRCT
43
Tower Research Capital (TRC)
New York
– -$13K -4,199 Closed
PCM
44
Prelude Capital Management
New York
– -$3K -900 Closed
Bank of America
45
Bank of America
North Carolina
– -$698 -238 -96%
IA
46
IFP Advisors
Florida
– -$325 -111 -98%
Citigroup
47
Citigroup
New York
– -$59 -20 -16%
CA
48
Calton & Associates
Florida
– +$29 +10 New
WWMSC
49
Wagner Wealth Management (South Carolina)
South Carolina
– +$47 +16 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
– +$64 +22 +122%
1
2
3

CTIC Hedge Fund Activity: Q4 2017 in Review

53 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2017, worth a combined $52.7M — down 9.7% from $58.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CTIC positions and 4 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $2.47M. The largest seller was Vanguard Group, cutting an estimated $660K.

  • 53 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2017, up from 42 in Q3 2017.
  • Funds reported $52.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2017, down 9.7% quarter-over-quarter.
  • 15 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2017 and 4 closed out, a net change of +11 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2017 was Stonepine Capital Management, an estimated $2.47M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2017 was Vanguard Group, an estimated $660K sold.

Based on aggregated 13F filings for Q4 2017.